Drugs / VVD-133214
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06004245 | Jan 2024 → May 2027 expected | colorectal cancer | Vividion Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VVD-133214 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06004245 ↗ |
| Route | Oral | “VVD-133214 will be administered orally and once daily (QD) in 3-week cycles.” NCT06004245 ↗ |
| Target | WRN | “VVD-133214 is an oral drug that acts on a protein called Werner (WRN), which may promote the growth of cancers that are MSI and/or dMMR.” NCT06004245 ↗ |